BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Comparative Efficacy of Ovule vs Tablet
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2015-08-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 466
- Registration Number
- NCT00755053
To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 409
- Registration Number
- NCT00754065
- Locations
- 🇨🇦
Regina Medical Centre, Regina, Saskatchewan, Canada
🇺🇸Adam Patterson OB-GYN, Memphis, Tennessee, United States
🇺🇸Clinical Research of Philadelphia, LLC, Philadelphia, Pennsylvania, United States
Single/Multiple Dose Bioavailability Trial
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-12
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT00751556
Naproxen Sodium Extended-Release Actual Use Study
- First Posted Date
- 2008-09-12
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 497
- Registration Number
- NCT00751400
Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
Phase 2
Completed
- Conditions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 150
- Registration Number
- NCT00751205
Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control.
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-10
- Last Posted Date
- 2014-12-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 405
- Registration Number
- NCT00750113
Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-08
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT00748046
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 168
- Registration Number
- NCT00744939
Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2015-11-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 150
- Registration Number
- NCT00738400
Inhibition of Ovulation, Patch, Ethinylestradiol and Gestodene
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 17
- Registration Number
- NCT00729404
© Copyright 2024. All Rights Reserved by MedPath